<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00146601</url>
  </required_header>
  <id_info>
    <org_study_id>04-075</org_study_id>
    <nct_id>NCT00146601</nct_id>
  </id_info>
  <brief_title>Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer</brief_title>
  <official_title>A Phase II Study of Fulvestrant in Premenopausal Women With Hormone Receptor-Positive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lowell General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the effectiveness and safety of fulvestrant in&#xD;
      premenopausal women with advanced breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will receive an injection of fulvestrant on first day of treatment and then again 2&#xD;
      weeks later and again 2 weeks after that. Then patients will receive injections every 4&#xD;
      weeks.&#xD;
&#xD;
      Routine blood tests will be performed each time an injection is given.&#xD;
&#xD;
      Patients will be required to complete a hot flash diary, recording the number and severity of&#xD;
      hot flashes they experience on a daily basis.&#xD;
&#xD;
      After every 12 weeks of treatment, patients' disease will be assessed by x-rays or scans. If&#xD;
      there is no disease progression, the patient will continue to receive injections every 4&#xD;
      weeks with reassessment every 8 weeks.&#xD;
&#xD;
      Patients will continue to receive treatment as long as there is no disease progression or&#xD;
      serious side effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To examine the clinical benefit and response rate of hormone receptor-positive metastatic breast cancer previously treated with anti-estrogen therapy in premenopausal women to treatment with fulvestrant</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the safety, time-to-progression, and duration of response for this patient population</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed invasive breast cancer, with stage IV&#xD;
             disease.&#xD;
&#xD;
          -  Tumors must be positive for estrogen receptors, progesterone receptors, or both.&#xD;
&#xD;
          -  Patients must be premenopausal.&#xD;
&#xD;
          -  Prior anti-estrogen therapy (with or without ovarian suppression)&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm3&#xD;
&#xD;
          -  Age older than 18 years&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hormonal treatment for metastatic disease&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Postmenopausal&#xD;
&#xD;
          -  Concurrent hormonal therapy or chemotherapy&#xD;
&#xD;
          -  Prior fulvestrant therapy&#xD;
&#xD;
          -  More than three prior chemotherapy regimens for metastatic disease&#xD;
&#xD;
          -  Concurrent, long-term anticoagulation therapy&#xD;
&#xD;
          -  Severe, uncontrolled intercurrent illness&#xD;
&#xD;
          -  History of hypersensitivity to castor oil&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig A. Bunnell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lowell General Hospital</name>
      <address>
        <city>Lowell</city>
        <state>Massachusetts</state>
        <zip>01854</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2005</study_first_posted>
  <last_update_submitted>December 20, 2007</last_update_submitted>
  <last_update_submitted_qc>December 20, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2007</last_update_posted>
  <keyword>Fulvestrant</keyword>
  <keyword>Advanced breast cancer</keyword>
  <keyword>Invasive breast cancer</keyword>
  <keyword>Stage IV Breast Cancer</keyword>
  <keyword>Hormone Receptor-Positive Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

